Episode 88
On this week’s Biotech Hangout, Daphne Zohar, Josh Schimmer, Grace Colon, Paul Matteis and guest host Yuval Cohen, Corbus CEO, discuss the latest industry news including Corbus’ recent data and offering, plus Immunocore’s private offering ($352M), Vaxcyte’s public offering ($750M) and Alto Neuroscience’s IPO ($120M). They also cover Evaluate’s top 10 most anticipated drug list, Vertex’s non-opioid drug meets its goal in trials, Dyne Therapeutics weighs takeover interest options and Biogen ends development and sales of Alzheimer’s Disease drug. The hosts debate whether the week’s deals (Regeneron buying 2seventy bio’s pipeline and Protagonist Therapeutics and Takeda’s licensing deal) create or destroy shareholder value. Other topics of discussion include biotech advocacy, including bipartisan R&D tax credit restoration bill and Janet Woodcock’s exit interview, plus Vanda Pharmaceuticals’ claim against the FDA. *This episode aired on February 2, 2024
Available Results
Generated results are saved to the knowledge database for reuse and search.
Extract Knowledge
Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.